Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
Kyungpook National University Hospital
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
61Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01421940CT.gov The Efficacy of Penile Rehabilitation Using Udenafil After Total Mesorectal Excision of Rectal Cancer | — | Completed | — | — | — |
NCT00607282CT.gov Efficacy of Udenafil After Radical Resection for Sigmoid Colon and Rectal Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Rectal Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Udenafil (this asset) | Kyungpook National University Hospital | Approved | BB · 66 |
| Capecitabine | Gustave Roussy, Cancer Campus, Grand Paris | P4 | BBB |
| Fluorouracilum | Gustave Roussy, Cancer Campus, Grand Paris | P3 | BBB |
| Floxuridine | City of Hope Medical Center | P2 | BBB |
| Oxaliplatin | Gustave Roussy, Cancer Campus, Grand Paris | P3 | BBB |
| Irinotecan | SCRI Development Innovations, LLC | P3 | BB |
| Cetuximab | Tang-Du Hospital | P2 | BB |
| Panitumumab | Grupo Espanol Multidisciplinario del Cancer Digestivo | P2 | BB |
| Pertuzumab | SWOG Cancer Research Network | P2 | BB |
+42 more in the Rectal Carcinoma cohort
Other indications for Udenafil
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Prostate Cancer | — | P4 | BB · 65 |
| Erectile Dysfunction | — | P2 | B · 57 |
| Sigmoid Colon Cancer | — | P2 | B · 57 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Udenafil in Rectal Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/udenafil-rectal-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →